Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Novel Vaccine ConceptsFree AccessLive Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in HumansJinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark ConnorsJinghe HuangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Byong KangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Adam WheatleyNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Sandeep NarpalaNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Adrian McdermottNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, April PooleNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Robert BailerNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Richard KoupNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Stephen MiguelesNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Marc GurwithPaxVax Inc., La Jolla, CA, United StatesSearch for more papers by this author, and Mark ConnorsNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5073.abstractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail OA16.01Background: Induction of durable antibody responses capable of neutralizing diverse HIV-1 isolates is the most important goal in HIV vaccinology. Broad and potent HIV Env-specific antibodies isolated from humans are characterized by binding to conserved sites on Env and by high levels of hypermutation. Live virus recombinant vectors may provide prolonged exposure to transgene-encoded antigen and may more potently drive affinity maturation than non-replicating vectors. We report results of a small Phase 1 trial of mucosal immunization with live adenovirus type 4 encoding influenza H5 HA (Ad4-H5-Vtn) as a model antigen. We explored its ability to induce durable, broad neutralizing antibody responses through upper respiratory tract application.Methods: Live Ad4-H5Vtn (103-108 viral particles (VP)) was administered by tonsillar swab or by nasal spray in a dose escalation study. Controls received (1010 VP) as enteric-coated capsules. Neutralizing antibodies were measured by a pseudotype HA lentiviral vector system. B cells were isolated using fluorescent HA probes. Immunoglobulin genes were cloned for mutation analysis, and re-expressed to measure neutralization potency and breadth.Results: The vaccine was well tolerated and symptoms were consistent with mild URI. Tonsillar and nasal immunizations were the most immunogenic routes inducing neutralizing antibody responses at day 60 (ID50=809 and 666 respectively) which rose during the first 6 months. B cells that expanded early were specific for both H1 and H5 and were directed to the conserved stalk, with H5 HA-monospecific cells expanding by 6 months. The median level of hypermutation was 3.6% compared to germline at week 4 and 7.4% at weeks 34–52. However, some antibodies contained 13–34% mutation and neutralized group 1 and 2 viruses.Conclusions: A single dose of live recombinant Ad4-H5 can induce highly mutated antibodies, suggesting that mucosal administration is a promising platform for the induction of HIV-specific neutralizing antibodies.FiguresReferencesRelatedDetails Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Jinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark Connors.Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans.AIDS Research and Human Retroviruses.Oct 2014.A44-A44.http://doi.org/10.1089/aid.2014.5073.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

Highly Active Antiretroviral Therapy 1-Infected Patients Treated with Prolonged Human Immunodeficiency Virus Type vCP 1452 and Recombinant gp 160 in Newly Safety and Immunogenicity of ALVAC

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.

Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study

Long-acting HIV Fusion Inhibitor Albuvirtide Combined with Ritonavir-Boosted Lopinavir for HIV-1-infected Patients after Failing the First-Line Antiretroviral Therapy: 48-Week Randomized, Controlled, Phase 3 Non-Inferiority TALENT Study

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial

A D-peptide-based HIV Gelatinous Combination Vaccine Improves Therapy in ART-delayed Macaques of Chronic Infection

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Expression of CD40L by the ALVAC-SIV vector abrogates T cell responses in 1 macaques 2

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques

Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study

Open-Label Phase II Trial of Amprenavir, Abacavir, and Fixed-Dose Zidovudine/Lamivudine in Newly and Chronically HIV-1–Infected Patients

Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro